Consistent with these previous findings, which suggest that CD47 targeting represents a potentially effective therapeutic strategy, intraperitoneally administered anti‐CD47 mAb did not promote macrophage phagocytosis of gastrointestinal cancer cells in our syngeneic immunocompetent mouse model, although cancer cells incubated with anti‐CD47 mAb prior to inoculation were susceptible to macrophage‐mediated phagocytosis. Here, CD47 is linked to cancer.